Edgar Filing: EPIX Pharmaceuticals, Inc. - Form 4

EPIX Pharmaceuticals, Inc. Form 4 November 06, 2006

November 06	6, 2006											
FORM 4 UNITED STATES SECURITIES AND EXCHANCE COMMISSION										OMB APPROVAL		
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								OMB Number:	3235-0287			
Check thi if no long subject to Section 10 Form 4 or Form 5 obligation	F CHANGES IN BENEFICIAL OWN SECURITIES Section 16(a) of the Securities Exchange Public Utility Holding Company Act of						e Act of 1934,	Expires: Estimated a burden hou response	January 31 200 ed average hours per			
may conti See Instru 1(b).	inue. Section 1		of the In	•		•				11		
(Print or Type R	(lesponses)											
1. Name and Address of Reporting Person <u>*</u> Schor Chen			2. Issuer Name and Ticker or Trading Symbol EPIX Pharmaceuticals, Inc. [EPIX]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Chec									
	HARMACEU' GUIRE ROAD		(Month/D 11/02/20	-)				Director X Officer (give below) Chief		Owner er (specify er	
(Street)			4. If Ame	4. If Amendment, Date Original					6. Individual or Joint/Group Filing(Check			
LEXINGTO	Filed(Mon	th/Day/Y	ear)				Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(State)	(Zip)	Tabl	e I - Nor	1-De	erivative S	Securi	ties Acq	uired, Disposed of	f, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)		2. Transaction Date 2A. Deemed Month/Day/Year) Execution Date, if any (Month/Day/Year)		3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or Code V Amount (D) Price				of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common Stock	11/02/2006			M	·	15,000	A	\$ 0.98	83,937	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount o Underlying Securities (Instr. 3 and 4)			
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Share		
Stock Option (Right to buy)	\$ 0.98	11/02/2006		М	15,000	12/16/2004 <u>(1)</u>	09/23/2014	Common Stock	15,000		
Reporting Owners											
Reporting Owner Name / Address				Relationships							
		Director 1	0% Owner	Officer	0	ther					

Chief Business Officer

Edgar Filing: EPIX Pharmaceuticals, Inc. - Form 4

Schor Chen C/O EPIX PHARMACEUTICALS, INC. 4 MAGUIRE ROAD LEXINGTON, MA 02421

Signatures

/s/ Michael Berdik, Attorney-in-Fact

11/03/2006

<u>**Signature of Reporting Person</u>

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The option vested as to 25% of the shares on December 16, 2004 and vests as to 1/48th of the remaining shares each month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.